MNPR News

Just two micro-cap companies entered the public markets in the last week before the holidays kick off, led by oncology biotech Monopar Therapeutics (MNPR) which popped 231% on its first day, the biggest since 2005. One company submitted an initial filing. After previously postponing its IPO twice, micro-cap biotech Monopar Therapeutics...read more

Monopar Therapeutics, which is developing therapies for chemotherapy-induced mucositis and cancers, popped 231% on Friday, the best first-day pop for an IPO since Baidu in 2005. The company raised $9 million by offering 1.1 million shares at $8, the low end of the range of $8 to $10, to command an $89 million market value. The pop is likely due in part to the extremely low...read more

Monopar Therapeutics, which is developing therapies for chemotherapy-induced mucositis and cancers, raised $9 million by offering 1.1 million shares at $8, the low end of the range of $8 to $10, to command an $89 million market value. Insiders indicated on $6 million worth of shares in the offering (67%). Monopar Therapeutics plans to list on the Nasdaq under the symbol MNPR....read more

Just two micro-cap companies are expected to IPO as we enter the last week before the holidays. Micro-cap onshore E&P Indonesia Energy (INDO) is expected to raise $15 million at a $75 million market cap. The company operates one production block and one exploration block, and production peaked at 400 BOPD in 2018. In its second IPO revival,...read more